View in EDS

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).

Saved in:
Bibliographic Details
Title: Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Authors: Schwebke, Jane R1, Sobel, Ryan2, Gersten, Janet K3, Sussman, Steven A4, Lederman, Samuel N5, Jacobs, Mark A6, Chappell, B Todd7, Weinstein, David L8, Moffett, Alfred H9, Azie, Nkechi E10, Angulo, David A10, Harriott, Itzel A10, Borroto-Esoda, Katyna11, Ghannoum, Mahmoud A12, Nyirjesy, Paul2, Sobel, Jack D13 jsobel@med.wayne.edu
Source: Clinical Infectious Diseases. Jun2022, Vol. 74 Issue 11, p1979-1985. 7p.
Database: Environment Complete
Description
ISSN:10584838
DOI:10.1093/cid/ciab750